Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents

BACKGROUND: Response to cetuximab (Erbitux®) and panitumumab (Vectibix®) varies among individuals, and even those who show response ultimately gain drug resistance. One possible etiologic factor is differential interaction between the drug and target. We describe the development of an assay based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Noh Jin, Wang, Xiuqiang, Diaz, Angelica, Goos-Root, Dana M., Bock, Christopher, Vaught, Jonathan D., Sun, Weimin, Strom, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749190/
https://www.ncbi.nlm.nih.gov/pubmed/23990977
http://dx.doi.org/10.1371/journal.pone.0071703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749190/
https://www.ncbi.nlm.nih.gov/pubmed/23990977
http://dx.doi.org/10.1371/journal.pone.0071703

Ejemplares similares